KR20230131207A - ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체 - Google Patents

ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체 Download PDF

Info

Publication number
KR20230131207A
KR20230131207A KR1020237023856A KR20237023856A KR20230131207A KR 20230131207 A KR20230131207 A KR 20230131207A KR 1020237023856 A KR1020237023856 A KR 1020237023856A KR 20237023856 A KR20237023856 A KR 20237023856A KR 20230131207 A KR20230131207 A KR 20230131207A
Authority
KR
South Korea
Prior art keywords
amino acid
ser
gly
seq
multispecific antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237023856A
Other languages
English (en)
Korean (ko)
Inventor
신지 소가
다케시 시게나가
다케시 쓰쓰미
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20230131207A publication Critical patent/KR20230131207A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020237023856A 2021-01-13 2022-01-12 ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체 Pending KR20230131207A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2021-003805 2021-01-13
JP2021003805 2021-01-13
PCT/JP2022/000661 WO2022153997A1 (ja) 2021-01-13 2022-01-12 ＡｃｔＲＩＩＡ、ＡｃｔＲＩＩＢ及びＦｎ１４に結合する多重特異性抗体

Publications (1)

Publication Number Publication Date
KR20230131207A true KR20230131207A (ko) 2023-09-12

Family

ID=82448440

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237023856A Pending KR20230131207A (ko) 2021-01-13 2022-01-12 ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체

Country Status (9)

Country Link
US (1) US20240092916A1 (https=)
EP (1) EP4279594A4 (https=)
JP (1) JPWO2022153997A1 (https=)
KR (1) KR20230131207A (https=)
CN (1) CN116802298A (https=)
AU (1) AU2022207252A1 (https=)
CA (1) CA3207850A1 (https=)
MX (1) MX2023008372A (https=)
WO (1) WO2022153997A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026099A1 (en) 2011-08-23 2013-02-28 Transbio Ltd Fn14 binding proteins and uses thereof
WO2017081624A1 (en) 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
WO2020090892A1 (ja) 2018-10-31 2020-05-07 アステラス製薬株式会社 抗ヒトＦｎ１４抗体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20120532A1 (es) * 2009-04-27 2012-05-18 Novartis Ag ANTICUERPOS ANTI-ActRIIB
NZ703724A (en) * 2012-06-11 2017-06-30 Amgen Inc Dual receptor antagonistic antigen-binding proteins and uses thereof
HK1219280A1 (zh) * 2013-08-14 2017-03-31 Novartis Ag 治疗偶发性包涵体肌炎之方法
KR20200118423A (ko) * 2018-01-08 2020-10-15 난징 레전드 바이오테크 씨오., 엘티디. 다중특이성 항원 결합 단백질 및 이의 사용 방법
TW202031684A (zh) * 2018-12-20 2020-09-01 日商協和麒麟股份有限公司 Fn14抗體及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013026099A1 (en) 2011-08-23 2013-02-28 Transbio Ltd Fn14 binding proteins and uses thereof
WO2017081624A1 (en) 2015-11-11 2017-05-18 Novartis Ag Uses of myostatin antagonists, combinations containing them and uses thereof
WO2020090892A1 (ja) 2018-10-31 2020-05-07 アステラス製薬株式会社 抗ヒトＦｎ１４抗体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Amato AA et al., Neurology. (미국) 2014, Vol. 83, p. 2239-2246
Bonald P et al., Dis Model Mech. (영국) 2013, Vol. 6, p. 25-39
Hanna MG et al., Lancet Neurol. (영국) 2019, Vol. 18, p. 834-844
Morosetti R et al., Am J Pathol. (미국) 2012, Vol. 180, p. 1603-1613
Naddaf E et al., Neurotherapeutics. (미국) 2018, Vol. 15, p. 995-1005
Sato S et al., Front Immunol. (스위스) 2014, Vol. 5, Article 18

Also Published As

Publication number Publication date
CA3207850A1 (en) 2022-07-21
AU2022207252A9 (en) 2024-10-17
AU2022207252A1 (en) 2023-08-03
EP4279594A4 (en) 2024-11-27
US20240092916A1 (en) 2024-03-21
EP4279594A1 (en) 2023-11-22
CN116802298A (zh) 2023-09-22
WO2022153997A1 (ja) 2022-07-21
MX2023008372A (es) 2023-07-26
JPWO2022153997A1 (https=) 2022-07-21

Similar Documents

Publication Publication Date Title
AU2011311673B2 (en) Antibodies against human TWEAK and uses thereof
JP2019147801A (ja) 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
US8883976B2 (en) Antibodies against human tweak and uses thereof
JP2014522236A (ja) 抗神経成長因子抗体並びに前記抗体の製造及び使用方法
TWI843763B (zh) 抗人類Fn14抗體
KR20170029508A (ko) 신규 항인간 Tie2 항체
KR20230029671A (ko) 항-인간 nr1 항체 유도체
EP3647323A1 (en) Anti-gitr antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP3112462A1 (en) Novel bispecific antibody binding to human tlr2 and human tlr4
KR20230131207A (ko) ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체
RU2787044C2 (ru) АНТИТЕЛО ПРОТИВ Fn14 ЧЕЛОВЕКА
BR122025002878B1 (pt) Usos de compostos antagonistas de gitr, combinações e kits
TW201321406A (zh) 腫瘤壞死因子抗體及使用其之方法
BR112023013294B1 (pt) Compostos antagonistas de gitr, composições que os compreendem, ácidos nucleicos, vetores, e processos de produção dos compostos
HK40050252A (en) Anti-human fn14 antibody

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230713

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application